Francisella tularensis is one of the most infectious bacteria known — a single cell can cause disease. That's why it's classified as a Category A bioterrorism agent. The tularemia market report by MRFR shows that serological testing is the largest diagnosis method, but molecular diagnostics (PCR) is the fastest‑growing. The market is $146 million and will hit $243.5 million by 2035, growing at 4.76% CAGR. Why the steady rise? Because public health agencies are stockpiling diagnostics and treatments.

What's driving growth? Antibiotic therapy is the largest treatment segment, but supportive care is the fastest‑growing — as hospitals improve their management of severe cases. The tularemia market analysis highlights that ulceroglandular tularemia is the most common infection type, but pneumonic tularemia is the fastest‑growing — because it can be aerosolized and has the highest mortality.

What's new? Rapid point‑of‑care tests that detect tularemia antigens in 30 minutes, without a lab. Also, next‑generation sequencing (NGS) for outbreak investigation.

The bottom line: tularemia is rare but serious. If you hunt, trap, or hike in endemic areas, wear gloves and avoid handling sick animals. And if you get a sudden fever with an ulcer, tell your doctor about animal exposure.